Moreover, these cells elevate the expression of tumor PD-L1 or T cell PD-1 when combined with immune checkpoint inhibitors, a strategy that has shown superior outcomes in tumor therapy [50, 125]. This evidence concerns the gene CD274 and neoplasm.